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Summary. A series of 55 randomly chosen radical prosta- 
tectomy specimens was analyzed for expression of pro- 
state-specific antigen (PSA) by immunohistochemical 
techniques. Tissue sections were selected in such a manner 
that in addition to glandular benign prostatic hyperplasia 
(BPH), one or more different prostatic turnout growth 
patterns were present. Four monoclonal antibodies, di- 
rected against three different PSA epitopes, and one 
polyclonal anti-PSA antiserum were used. Expression of 
PSA was compared with that of prostate-specific a id 
phosphatase (PAP), recognized by two different polyclo- 
nal antisera. A critical dilution aimed at a maximum of 
staining intensity on BPH tissue sections was chosen for 
all antibodies. Anti-PSA and anti-PAP antisera stained 
essentially all BPH samples (over 90 %). Irrespective of the 
nature of the antibodies used, PSA expression was found 
to be decreased in prostatic carcinoma. A clear cut 
relationship was found between immunoreactivity for 
PSA and the degree of differentiation f the tumour area. 
Under the experimental conditions used the PSA mono- 
clonal antibodies stained only 1 out of 10 undifferentiated 
carcinomas, whereas 50% to 70% of the well- and 
moderately-differentiated carcinomas howed immuno- 
reactivity. This correlation was less pronounced with the 
PAP staining pattern. If the PSA antibody titer was raised 
the percentage of clearly staining undifferentiated carci- 
nomas could be considerably increased (up to 60%- 
100%), indicating that PSA expression is not absent, but 
lowered in most (if not all) undifferentiated carcinomas. 
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from the cDNA sequence has been elucidated [18, 24, 30]. 
PSA is exclusively secreted by the epithelial cells of the 
prostatic gland. Because of its tissue-specific expression 
pattern, PSA became of interest as being a prostate- 
specific (tumour) marker. Availability of specific polyclo- 
nal and monoclonal antibodies also made its immunohis- 
tochemical detection in neoplastic and non-neoplastic 
prostatic tissue possible [6, 11, 12, 22]. In addition, it 
turned out that the presence of PSA in sera of patients 
could be used for monitoring the natural course of 
prostatic ancer and to evaluate the success or failure of 
therapeutic (often endocrine) regimens [27]. 
Especially because of the general acceptance ofPSA as 
being the most reliable and sensitive prostate (tumour) 
marker in serological assays, detailed analysis of PSA 
expression in prostatic tumours is of high importance. 
Several studies have been presented aiming to gain a better 
insight into the specificity and sensitivity of PSA ex- 
pression in prostatic tumours [1, 2, 5, 7, 8-10, 16, 23, 26]. 
To extend our knowledge further in this regard we 
investigated PSA expression in tissue sections derived 
from radical prostatectomy preparations. Prostatectomy 
was performed for localized prostatic arcinoma. Prosta- 
tic carcinomas are often composed of different growth 
patterns within a single tumour. This provided an ideal 
opportunity to compare in detail the immunohistochemi- 
cal levels of PSA with prostatic turnout differentiation 
status. Since no consensus has been reached concerning 
the most suited histological grading system for prostatic 
cancer, immunohistochemical results were not correlated 
with grading scores. In addition to PSA expression we also 
studied prostate-specific acid phoshatase (PAP) ex- 
pression in this material. 
Prostate-specific antigen (PSA) was first described by 
Wang and co-workers [21,28, 29]. It belongs to a family of 
kallikrein-like serine proteases and has a molecular weight 
of 33-35 kD [3, 30]. Recently, the primary structure of the 
PSA protein obtained by direct sequencing or deduced 
Materials and methods 
Prostatic tissue 
Prostatic tissues used in this study were obtained from prostatec- 
tomy specimens. Fifty-five patients (randomly selected from a much 
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Table 1. Distribution of different histological patterns of prostatic 
carcinoma and benign prostatic hyperplasia in prostatectomy 
specimens obtained from 55 patients with localized carcinoma 
N 
Well differentiated a enocarcinoma (WDA) 39 
Moderately differentiated a enocarcinoma (MDA) 43 
Poorly differentiated a enocarcinoma (PDA) 16 
Undifferentiated carcinoma (UC) 10 
Clear cell carcinoma (CCC) 12 
Solid tumour areas (STA) 8 
Cribriform carcinoma (CC) 19 
Benign prostatic hyperplasia (BPH) 55 
larger series) with clinically staged localized prostatic arcinoma 
(T 1, T2 and T3) were treated by radical prostatectomy in the years 
1980-1987 at the Department of Urology of Erasmus University 
Rotterdam. Patients did not receive any therapy prior to surgery. 
All immunohistochemical assays were performed on surgical 
prostatectomy specimens. These specimens were routinely fixed in 
10% buffered formalin, sectioned perpendicular to the prostatic 
urethra and submitted completely for histological examination. 
Tissues were routinely handled and stained with haematoxilin- 
azofloxin. The number of sections per specimen varied from 24 to 43. 
Of each specimen two slides were selected in which equally 
distributed glandular benign prostatic hyperplasia (BPH) and 
tumour areas were present. In all slides different subtypes of 
prostatic carcinoma based predominantly upon histological features 
could be distinguished. Apart from well-, moderately-, and poorly- 
differentiated a enocarcinomas,  cribriform growth pattern, and 
an undifferentiated ( iffusely infiltrating variant without acinar 
formations) subtype were present in our material. In addition, a 
growth variant characterized bysolid undifferentiated tumour areas 
(medullary growth pattern) and the so-called hypernephroid or clear 
cell type (showing resemblance with adenocarcinoma renis) were 
discerned (see Table 1). Turnout patterns with typical endometrioid 
features were not present in our material. 
Research Laboratory, Cambridge, Massachusetts (Com-PAP(pc)). 
Additionally, a rabbit polyclonal ntiserum (PAP(pc)) was prepared 
in our own laboratory. PAP was purified from BPH tissue by affinity 
chromatography using a PAP-specific McAb, which was able to bind 
PAP but did not recognize PAP in formalin-fixed tissue. Specificity 
of this polyclonal antiserum was assessed by means of the Western 
blot technique and immunohistochemistry. As cross-reactivity exist- 
ed at immunohistochemical level, the rabbit anti-PAP serum was 
extensively adsorbed with acetone-dried human pancreatic and 
kidney tissue powder. The resulting purified antiserum (PAP(pc)) 
showed no reactivity with pancreatic sland cells, kidney tubules, 
mast cells or granulocytes. 
As described above for the PSA antibodies, PAP antibodies were 
used in such a dilution that further lowering of the concentration 
resulted in a decrease of staining intensity of BPH control tissue. 
Immunohistochemistry. Consecutive paraffin sections were cut at 5 
gm thickness. After rehydration of the deparaffinized sections, the 
sections were treated for 20 rain with absolute methyl alcohol, 
containing 0.3% H202 to block endogenous peroxidase activity. 
Subsequently, sections were rinsed in PBS. Primary antibodies were 
applied for 1 h at 37~ Subsequently, slides were incubated with 
peroxidase conjugated antisera (P-rabbit anti-mouse or P-conjuga- 
ted swine anti-rabbit; Dakopatts Denmark) for 1 hr at room 
temperature. Peroxidase activity was visualized by incubating the 
sections in Tris-HC1 buffer (0.05 M, pH 7.4) containing 0.0125% 
3,3'-diamino benzidine tetrahydrochloride (Fluka AG, Switserland) 
activated by 0.03 % H202 (10 min at room temperature). In all cases a
brief nuclear counter stain with Mayer's haematoxilin was per- 
formed. 
Finally, sections were dehydrated, mounted in malinol and 
examined microscopically. Appropriate positive (BPH) and nega- 
tive control slides were processed in an identical manner. Intra- 
epithelial staining intensities were judged subjectively as0 (absent), 1 
(faint), 2 (moderate), or 3 (strong). For purpose of presentation 0 
and 1 were considered as negative, 2 and 3 as positive results. Since 
heterogeneity (variation in number of tumour cells that stain 
positively) even within the same histological subtype was often 
present, only areas with the highest staining intensity were judged in 
both BPH and prostatic arcinoma. 
Primary antibodies 
PSA specific antibodies. PSA purified from extracts of BPH tissue by 
affinity choromatography using the PSA-specific monoclonal nti- 
body ER-Prl (12) was applied to generate mouse monoclonal 
antibodies and a rabbit polyclonal antiserum (PSA(pc)) using 
standard procedures. Details will be published elsewhere. In short, 
specificity of the antibodies was checked by immuno-(Western-) 
blotting and immunohistochemistry using extracts and tissue sec- 
tions of malignant and non-malignant human tissues from different 
origins. Three monoclonal antibodies (ER-Pr8, 12 and 27) which 
showed the highest reactivity with formalin-fixed paraffin-em- 
bedded prostate tissue were analyzed in detail. All antibodies were 
reactive with a 33-35 kD protein, recognized as PSA. Monoclonal 
antibodies were of the IgG1 subclass. Ascites batches with high 
concentrations of monoclonal antibodies were used for further 
studies. The four monoclonal antibodies defined three unique 
antigenic determinants of PSA as established by competition ELISA 
assays. ER-Pr8 and ER-Pr27 were directed against the same PSA- 
epitope. Antibodies were titrated for optimalization of the most 
suitable dilution for immunohistochemistry. Dilutions of all antibo- 
dies were selected in such a manner that further lowering of the 
concentration resulted in a decrease of staining intensity of BPH 
control sections. 
PAP specific antibodies. A commercially available rabbit polyclonal 
antibody directed against PAP was obtained from Cambridge 
Results 
Histology of prostatectomy specimens 
It is well establ ished that prostate tumours are very 
heterogeneous. In the prostatectomy specimens investi- 
gated in this study, adjacent to prostat ic arc inoma, areas 
of prol i ferative benign epithelial g landular  structures 
(g landular-BPH) were present in all sections. In some 
areas groups of hyperplast ic glands were arranged in 
nodular  formations.  In the 55 cases examined, tumour  
heterogeneity was reflected by the large number  of 
different growth patterns present in each sample. 
A l though the subdivision of  growth characteristics of 
prostat ic carc inoma such as represented in Table 1 is 
somewhat arbitrary,  in our set of  tumours the whole range 
of  histological subtypes in nearly every combinat ion was 
detectable and varied from only 1 histological carc inoma 
type in 4 cases to 5 different patterns in 3 specimens. 
Adenocarc inomas with gland format ion,  irrespective 
their degree of  differentiation, were most frequently 
observed. Tumours consisting of  g landular  structures 
were subdivided into well-, moderately-  and poor ly-  
differentiated carcinomas based upon diameter of  tumour  
55" Table 2. Number of prostatectomy specimens (%) with indicated 
staining for PSA (scored 2 or 3)/total no specimens in benign 
prostatic hyperplasia (BPH) and prostatic arcinoma regardless its 
histological growth characteristics 
Antibodies BPH Carcinoma 
PSA(pc) 53/55 (96%) 41/55 (75%) 
ER-Prl 48/55 (87%) 35/55 (64%) 
ER-Pr8 50/55 (91%) 40/55 (73 %) 
ER-Prl 2 52/55 (95 %) 36/55 (65 %) 
ER-Pr27 54/55 (98 %) 41/55 (75%) 
glands and their resemblance to normal prostatic glandu- 
lar structures. A cribriform growth pattern was con- 
sidered as a seperate ntity. A total lack of glandular 
formations in tumour tissue was only found in 5 speci- 
mens. 
Expression of PSA in various prostate tumour growth 
patterns and BPH present in prostatectomy specimens 
The set of 55 prostatectomy preparations was analyzed for 
expression of PSA by immunohistochemical techniques 
using four different monoclonal antibodies directed 
against hree different epitopes and a polyclonal antise- 
rum (PSA(pc)) (see Materials and methods). In BPH 
tissue sections some heterogeneity in immunostaining 
patterns was observed with all antibody preparations 
used. This heterogeneity was most prominent when 
monoclonal antibody ER-Prl was applied. Heterogeneity 
was rarely detected in epithelial cells lining the same 
gland, but was observed as a variation of staining of 
different glands. The heterogeneity observed with mono- 
clonal antibody ER-Prl could partially be due to a less 
stable appearance of the PSA antigenic site recognized by 
this antibody. In spite of the presence of some unstained 
glands, essentially all (91%-98 %) BPH specimens exam- 
ined were clearly stained with three out of four monoclo- 
nal antibodies and the polyclonal antiserum against PSA. 
ER-Prl gave somewhat lower figures (Table 2 and Fig. 1). 
We examined PSA expression in prostatic arcinoma 
in the same tissue slides as used for the study of PSA in 
BPH. Without subdividing the tumour regions into 
different growth patterns, the immunostaining for PSA 
was scored between 64% and 75% of the sections 
examined (Table 2). Similarly as noted in BPH tissue 
sections, ER-Prl stained the smallest number of slides (35 
out of 55), whereas the polyclonal antiserum (PSA(pc)) 
and the monoclonal antibody ER-Pr27 showed the high- 
est percentage of positives (75 %). Figure 2 depicts four 
examples of lowered or even absent PSA staining in 
carcinoma reas as compared to the internal BPH control. 
If PSA expression was compared for the various tumour 
growth patterns as summariazed in Table 1 an interesting 
distribution could be observed (Fig. 1). Fifty to 70% of 
those tumour areas that consisted of glandular structures 
and designated as well- or moderately-differentiated de-
nocarcinomas stained positively for PSA. The variation of 
50 84 
45. 
40  
35-  
30" 
25" 
20" 
10 
5 '  
0 
1234 
BPH 
Illl 
12345 12345 12345 
WDA MDA PDA 
183 
12345 12345 12345 12345 
CCC STA CC UC 
Fig. 1. Schematic presentation of PSA-immunoractivity (scored 2 
and 3) in BPH areas and various growth patterns of prostatic 
carcinoma, determined by polyclonal (PSA(pc)) - and McAbs (ER- 
Prl, 8, 12, and 27). 1: PSA(pc); 2: ER-PrS; 3: ER-Pr 12; 4: ER-Pr27; 5: 
ER-Prl. Abbreviations ofgrowth patterns are as described inTable 
1. Number of staining tissue sections = l; total number of tissue 
sections 
staining scored in our series of poorly-differentiated 
adenocarcinoma is possibly due to some difficulties in 
determining the histological criteria for this subgroup. 
The same is true for the small group of solid undifferen- 
tiated tumours (Fig. 1). In general, however, this growth 
pattern showed a low percentage of positives. The cribri- 
form growing tumour areas also showed a low staining 
percentage (26 or less). 
The difference between PSA expression in tumour 
tissue and BPH tissue was most striking in the sections 
containing undifferentiated carcinoma. In the latter group 
almost none of the tumour areas could be stained. As 
stated in the method section we used PSA antibodies at 
such a concentration that further dilution would cause a 
decrease in the staining intensity of BPH controls. There- 
fore, the results obtained reflect he maximal difference in 
PSA expression detectable with immunohistochemical 
techniques in the various tumour growth patterns and 
BPH. 
To investigate the effect of antibody concentration on 
detection of PSA expression the 10 slides containing 
undifferentiated carcinoma reas were re-examined with a 
ten-fold higher PSA antibody concentration. Results are 
summarized in Table 3. All antibodies used showed 
essentially the same shift in staining intensity. At the low 
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Fig. 2a-d. Examples of diminished or absent (scored 1 or 0) PSA- 
immunoreactivity in growth patterns of prostatic arcinoma. At the 
right side of every photograph an area of BPH is present. Original 
magnification 150X. Selected antibody titers were based on maxi- 
mum staining in BPH areas, amoderately differentiated a enocarci- 
noma; section stained by the antibody ER-Pr27. b moderately 
differentiated a enocarcinoma; section stained by the antibody ER- 
Pr27. e Solid turnout areas; section stained by the antibody ER-Pr 12. 
d cribriform carcinoma; section stained by the antibody ER-Pr27 
antibody titer staining could only be detected in a small 
number of the undifferentiated carcinomas, whereas 
application of high antibody titers resulted in staining of 
the majority of the undifferentiated prostate tumours. It is 
obvious from these results that differences in PSA ex- 
pression level can only be clearly detected if carefully 
controlled experimental conditions are applied. 
Comparison of PSA and PAP expression 
in prostatic tumour sections 
Two different polyclonal antisera against PAP (Com- 
PAP(pc) and PAP(pc); see Materials and methods ection) 
were used for comparison of PAP expression with that of 
PSA in various prostate tumour growth patterns. Similar- 
ly as described for PSA antibodies, PAP antibodies were 
applied at such a concentration that further dilution 
would result in decreased staining of BPH tissue sections. 
Figure 3 shows an example of the immunostaining found 
with a PSA and a PAP antibody. In this particular turnout 
area PSA was absent using the initial antibody titer, 
whereas PAP could be readily demonstrated. Further 
results are presented in Fig. 4. Identical to PSA, PAP 
expression assessed by either antiserum was found to be 
lower in turnout areas as compared to BPH. However, the 
Table 3. Distribution of immunostaining intensity scores (scores 0and 1 are combined) of PSA within undifferentiated carcinoma reas 
assessed by polyclonal (PSA(pc)) and monoclonal ntibodies (ER-Prl2; ER-Pr8) using two different concentrations of the primary antibody 
0,1 2 3 0,1 2 3 
PSA(pc) 1:6400 7 3 0 PSA(pc) 1:640 0 8 2 
ER-Prl2 1:102.400 9 1 0 ER-Pr12 1:10.240 3 4 3 
ER-Pr8 1:51.200 9 1 0 ER-Pr8 1:5.120 4 4 2 
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Fig. 3 a and b. Prostatectomy tissue section showing BPH and an area 
of moderately differentiated adenocarcinoma. Consecutive slides 
were stained by the anti-PSA antibody ER-Prl2 a and the PAP(pc) 
antiserum b . Chosen antibody titers were based on maximum 
staining in BPH areas. In the tumor area PSA could not be 
demonstrated, whereas PAP could be detected more readily. Orig- 
inal magnification 150N 
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Fig. 4. Schematic presentation of PSA- and PAP immunoreactivity 
(scored 2 and 3) in BPH areas and various growth patterns of 
prostatic arcinoma, determined by polyclonal antibodies Corn- 
PAP(pc) (1), PAP(pc) (2) and PSA(pc) (3). Abbreviations of growth 
patterns are as described in Table 1. Number of staining tissue 
sections = I; total number of tissue sections = r] 
differences observed were much less pronounced. Com- 
parison of PSA and PAP expression in undifferentiated 
carcinoma and in cribriform carcinoma shows that the 
majority of sections examined were positively stained with 
PAP antibodies, whereas the PSA antibodies were in 
general negative (Figs. 1 and 4). Both antisera gainst PAP 
gave essentially identical results. From these data we 
concluded that, in contrast o PSA, PAP expression is 
considerably less correlated with tumor-differentiation. 
Discussion 
Although now accepted as a reliable marker for prostatic 
carcinoma both in serological and immunohistochemical 
assays the detailed possibilities of application of PSA 
expression as a tool for characterization f neoplastic ells 
of prostatic origin and its precise correlation with tumour 
differentiation are still a matter of dispute. This especially 
concerns fluctuation in PSA expression in various 
tumours and the sensitivity of PSA as compared to PAP. 
In this study PSA expression was investigated in various 
growth patterns of prostatic arcinoma present in prosta- 
tectomy specimens. Prostatectomy was performed with- 
out prior therapy. In general, several different growth 
patterns could be distinguished in each prostatectomy 
specimen and were often even present in one single tissue 
slide. As an internal control all tissue sections examined 
contained, in addition to turnout regions, areas of BPH. 
By this approach fluctuations in the data due to exper- 
imental artefacts or differences in the quality of the tissue 
slides could be reduced to a minimum. PSA expression 
was correlated to the differentiation status of a tumour 
area. Since consensus is lacking referring the most ap- 
propriate grading method for prostatic carcinoma no 
attempts were made to compare immunohistochemical 
findings with scores of one of the various grading systems 
described [13, 15, 19, 20]. 
The data obtained clearly show a difference in PSA 
expression i  BPH and prostatic arcinoma irrespective of 
its histological features. Most pronounced differences 
were detected between undifferentiated tumours and the 
BPH control. Under well-defined conditions (low anti- 
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body concentration) the majority of undifferentiated 
turnout areas were negative when stained with five 
different PSA antibodies. In most studies described so far, 
a much higher percentage of PSA positive tumours has 
been reported [1,7, 8, 10, 23], although in part of these less 
intense staining of less-differentiated tumours has been 
noticed. Two of the more recent studies mention the 
absence of PSA staining in (part of) undifferentiated 
tumours [9, 16]. Further experiments presented here 
clearly establish that choice of the antibody titer for 
immunohistochemical detection of PSA in turnout ma- 
terial is of utmost importance. If higher concentrations of
specific antibodies are used most of the undifferentiated 
tumour sections in prostatectomy specimens tain posi- 
tively. 
These data confirm and extend earlier observations 
that PSA is a very good marker for prostate carcinoma. 
Furthermore, the data presented here indicate that at least 
those monoclonal antibodies which are directed against 
dominant epitopes of PSA (in this study ER-Pr8 and ER- 
Pr27) are very useful in diagnostic pathology and do not 
differ in sensitivity from polyclonal antibodies. Our 
results may lend support o the assumption that a decrease 
of PSA concentration i  the sera of patients with prostatic 
carcinoma not always has to reflect a successful thera- 
peutic intervention, but may also be the result of domi- 
nant progressive growth of undifferentiated prostatic 
carcinoma. More extensive studies correlating immuno- 
histochemical data with PSA serum levels have to be 
initiated to gain better insight in this phenomenon. 
Moreover, it is our opinion that during monitoring of 
endocrine therapy special care must be taken in the 
accurate interpretation of a decrease of serum PSA 
concentration, especially since there are indications that 
PSA expression is influenced by hormones [14]. 
In contrast o the results obtained on PSA a definite 
relationship between histopathological growth patterns 
and PAP expression was less apparent. Even at the 
experimental conditions chosen which were optimal for 
the visualization of differential expression, the differences 
in PAP expression level in the various tumour sections 
were small. From our data it can only be concluded that in 
tumour regions PAP expression is slightly reduced. Our 
data support those earlier observations showing that in 
undifferentiated prostatic turnouts the presence of PAP- 
can be more easily detected than PSA [4, 5, 9, 14, 16, 17]. 
However, our findings contradict the reports of others in 
which no difference or even a better PSA staining was 
described in poorly- or undifferentiated prostatic arcino- 
mas [1, 2, 7, 8, 31]. Since the prostate specificity of PAP 
antibodies is sometimes questioned [25], we find it to be 
important to use both PAP and PSA as prostatic turnout 
markers. PAP expression might provide more informa- 
tion on the prostate origin of a tumour, whereas PSA 
expression (or its absence) seems to be better correlated 
with histological differentiation. 
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